ACQUIRED · 2020
Who Acquired Pharmaceutical Strategies Group 340B Link?
Omnicell, Inc. · $225.0M
The acquisition
Pharmaceutical Strategies Group 340B Link was acquired by Omnicell, Inc. in 2020 for $225.0M. at 6.40× revenue.
Pharmaceutical Strategies Group 340B Link at time of acquisition
Revenue
$35.0M
Deal value
$225.0M
Other acquisitions by Omnicell, Inc.
Recent transactions by the same buyer — useful for understanding their playbook and what they typically pay.
- MarkeTouch Media · 2022 · $82.0M
Similar pharmacy acquisitions
- University Compounding Pharmacy · acquired by Fagron in 2026 · $41.5M
- Choice Specialty Pharmacy Group · acquired by Better Choice Company, Inc. in 2025 · $28.0M
- Horizon Infusions · acquired by Rubicon in 2025 · $130.0M
- KabaFusion · acquired by Nautic Partners in 2025 · $2.20B
- Soleo Health · acquired by Court Square Capital and WindRose Health in 2025 · $1.10B
Run a valuation for a similar pharmacy business
Three fields, instant range, backed by 25,592 real M&A transactions including this one.
Open the pharmacy calculator →More on pharmacy valuations
- Value a medical practice
- Value a dental practice
- Value a veterinary practice
- Pharmacy valuation calculator· head-term variant
- Pharmacy median multiples· real-deal benchmarks
- How to value a pharmacy· long-form guide
Sourced from SEC filings and press releases. Full deal page.
Citation: ExitValue.ai. (2020). Pharmaceutical Strategies Group 340B Link acquired by Omnicell, Inc.. https://exitvalue.ai/acquired/pharmaceutical-strategies-group-340b-link